Thrivent Financial for Lutherans’s Protagonist Therapeutics PTGX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.13M	Sell	39,225 -1,155	-3%	-$102K	0.01%	1003
2025 Q4	$3.53M	Sell	40,380 -1,808	-4%	-$148K	0.01%	1100
2025 Q3	$2.8M	Sell	42,188 -3,388	-7%	-$193K	0.01%	1135
2025 Q2	$2.52M	Buy	45,576 +1,800	+4%	+$86.4K	0.01%	1198
2025 Q1	$2.12M	Sell	43,776 -2,290	-5%	-$96K	﹤0.01%	1260
2024 Q4	$1.78M	Sell	46,066 -191	-0.4%	-$8.33K	﹤0.01%	1517
2024 Q3	$2.08M	Buy	+46,257	New	+$1.87M	﹤0.01%	1410
2023 Q3	–	Sell	-73,381	Closed	-$2.03M	–	2484
2023 Q2	$2.03M	Sell	73,381 -27,612	-27%	-$691K	﹤0.01%	1325
2023 Q1	$2.32M	Hold	100,993	–	–	0.01%	1202
2022 Q4	$1.1M	Hold	100,993	–	–	﹤0.01%	1667
2022 Q3	$852K	Buy	+100,993	New	+$956K	﹤0.01%	1784

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Thrivent Financial for Lutherans's PTGX Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Protagonist Therapeutics (PTGX) stake by 2.9% in Q1 2026, selling an estimated $102K and leaving 39,225 shares worth $4.13M. The position accounts for 0.01% of the portfolio, ranked #1003.

Thrivent Financial for Lutherans first reported a position in PTGX in Q3 2022 and has held it in 11 quarters since. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Thrivent Financial for Lutherans held 39,225 shares of Protagonist Therapeutics worth $4.13M as of Q1 2026.
Thrivent Financial for Lutherans sold 1,155 Protagonist Therapeutics shares in Q1 2026, an estimated $102K.
Protagonist Therapeutics made up 0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1003 holding.
Thrivent Financial for Lutherans first reported a position in Protagonist Therapeutics in Q3 2022 and has held it in 11 quarters since.
319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.